VPM1002

Phase 3Biologic

SSerum Life Science Europe GmbH

VPM1002 is one of 39 biologic programs targeting Infectious Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Infectious DiseaseActive, not recruiting

COVID-19Active, not recruiting

Infectious DiseasePhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

VPM1002

SSerum Life Science Europe GmbH

Phase 3

2 2

Singulair

AstraZeneca

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Calciferol

Alnylam Pharmaceuticals

Preclinical

—6

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 7

Nitrostat

VViatris Specialty LLC

Preclinical

1 8

Piperacillin/tazobactam

Pfizer

Preclinical

1 9

Orap

Teva

Preclinical

1 10

Calcium

Eli Lilly

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity3 trials

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers

Completed·SSerum Life Science Europe GmbH·Phase 1·NCT00749034·80 enrolled

Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa

Completed·SSerum Life Science Europe GmbH·Phase 2·NCT01479972·48 enrolled

Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa

Completed·SSerum Institute of India Pvt. Ltd.·Phase 2·NCT02391415·416 enrolled

COVID-192 trials

Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity

Completed·UUniversity Health Network, Toronto·Phase 3·NCT04439045·122 enrolled

Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Unknown status·SSerum Life Science Europe GmbH·Phase 3·NCT04387409·59 enrolled

Efficacy and Safety2 trials

Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants

Completed·SSerum Institute of India Pvt. Ltd.·Phase 3·NCT04351685·6,940 enrolled

Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence

Completed·SSerum Institute of India Pvt. Ltd.·Phase 2/3·NCT03152903·2,000 enrolled

Infectious Disease1 trial

Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic

Completed·SSerum Life Science Europe GmbH·Phase 3·NCT04435379·2,038 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for VPM1002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VPM1002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VPM1002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Serum Life Science Europe GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: SSerum Life Science Europe GmbH

VPM1002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunogenicity3 trials

COVID-192 trials

Efficacy and Safety2 trials

Infectious Disease1 trial

References

Drug Info

Quick Facts

Related News